Skip to main content
Log in

Cost-Effectiveness of Prolonged Thromboprophylaxis After Cancer Surgery

  • Healthcare Policy and Outcomes
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Consensus guidelines recommend prolonged thromboprophylaxis for up to 4 weeks after major abdominopelvic cancer operations. Several factors impede widespread adoption of these guidelines. These include lack of awareness, cost, increased bleeding complications, increased incidence of heparin-induced thrombocytopenia, and poor patient compliance.

Methods

A cost-effectiveness model was constructed comparing four potential strategies to postdischarge thromboprophylaxis in surgical oncology patients: (1) low-molecular-weight heparin (LMWH) once daily; (2) low-dose unfractionated heparin (LDUH) three times daily; (3) oral aspirin once daily; or (4) no prolonged prophylaxis. Probabilities and costs were estimated on the basis of published literature and average Medicare reimbursement. The decision analysis was conducted from the perspective of the health care system, with the primary end point being cost per patient without venous thromboembolism (VTE). Sensitivity analyses tested the robustness of the results.

Results

LDUH was most cost-effective, saving $154 per patient without VTE compared with no prophylaxis. LMWH was not cost-effective, incurring a cost of $230 per patient without VTE compared with no prophylaxis. Aspirin was a viable alternative to LDUH, saving $123 compared with no prophylaxis. When poor compliance was considered, aspirin became the dominant strategy. Sensitivity analyses failed to show any instance where LMWH was cost-effective. In terms of population costs, widespread use of LDUH after discharge would save $30.3 million per year in the United States.

Conclusions

Although all chemical prophylaxis is effective in preventing VTE in the outpatient setting after cancer surgery, either LDUH or aspirin are the most cost-effective, depending on patient compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Osborne NH, Wakefiled TW, Henke PK. Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol. 2008;15:3567–78.

    Article  PubMed  Google Scholar 

  2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:381S–453S.

    Google Scholar 

  3. Khushal A, Quinlan D, Alikhan R, et al. Thromboembolic disease in surgery for malignancy—rationale for prolonged thromboprophylaxis. Semin Thromb Hemost. 2002;28:569–76.

    Article  PubMed  Google Scholar 

  4. Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev. 2002;28:141–4.

    Article  CAS  PubMed  Google Scholar 

  5. Bergqvist D, Agnelli G, Cohen AT, et al. for the ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975–80.

    Article  CAS  PubMed  Google Scholar 

  6. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. for the FAME investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4:2384–90.

    Article  CAS  PubMed  Google Scholar 

  7. Lausen I, Jensen R, Jorgense LN, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg. 1998;164:657–63.

    Article  CAS  PubMed  Google Scholar 

  8. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS Project. Ann Surg. 2006;243:89–95.

    Article  PubMed  Google Scholar 

  9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Venous thromboembolic disease, v.2.2008. http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf. Accessed 23 August 2009.

  10. Layman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490–505.

    Article  Google Scholar 

  11. Stratton MA, Anderson FA, Bussey HI. Prevention of venous thromboembolism. Adherence to the 1995 American College of Chest Physicians Consensus Guidelines for Surgical Patients. Arch Intern Med. 2000;160:334–40.

    Article  CAS  PubMed  Google Scholar 

  12. Kakkar AK, Levine M, Piedo HM, Wolfe R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8:381–8.

    Article  PubMed  Google Scholar 

  13. Wolff RA. Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat Rev. 2003;29:7–9.

    Article  PubMed  Google Scholar 

  14. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 2001;120:1964–71.

    Article  CAS  PubMed  Google Scholar 

  15. Amin A, Stemkowski S, Lin J, Yang G. Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hematol Oncol. 2008;6:910–20.

    PubMed  Google Scholar 

  16. Mismetti P, Leporte S, Darmon JT, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88:913–30.

    Article  CAS  PubMed  Google Scholar 

  17. Manganelli D, Paxxagli M, Mazzantini D, et al. Prolonged prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration. 1998;65:369–74.

    Article  CAS  PubMed  Google Scholar 

  18. Bennett CL, Yarnold PR, Evens AM, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296:2558–60.

    Article  CAS  PubMed  Google Scholar 

  19. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295–302.

    Article  Google Scholar 

  20. Warkentin TE, Kelton JG. A 14-year study of heparin-induce thrombocytopenia. Am J Med. 1996;101:502–7.

    Article  CAS  PubMed  Google Scholar 

  21. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–5.

    Article  CAS  PubMed  Google Scholar 

  22. Comp PC, Spiro TE, Friedman RJ, et al. for the Enoxaparin Clinical Trial Group. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am. 2001;83:336–45.

    PubMed  Google Scholar 

  23. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348:224–8.

    Article  CAS  PubMed  Google Scholar 

  24. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery—results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®). Thromb Haemost. 1997;77:26–31.

    CAS  PubMed  Google Scholar 

  25. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696–700.

    Article  CAS  PubMed  Google Scholar 

  26. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) study. Thromb Res. 1998;89:281–7.

    Article  CAS  PubMed  Google Scholar 

  27. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. Arch Intern Med. 2000;160:2208–15.

    Article  CAS  PubMed  Google Scholar 

  28. Heit JA, Elliott CG, Trowbridge AA, et al. for the Ardeparin Arthroplasty Study Group. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomised, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:853–61.

    CAS  PubMed  Google Scholar 

  29. Martel N, Lee J, Wells PS. Risk for Heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710–5.

    Article  CAS  PubMed  Google Scholar 

  30. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.

    Article  CAS  PubMed  Google Scholar 

  31. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.

    Article  CAS  PubMed  Google Scholar 

  32. Red Book. Montvale, NJ: Thompson, 2006.

  33. Centers for Medicare and Medicaid Services. Medicare provider analysis and review database. http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/03_MEDPAR.asp. Accessed 23 August 2009.

  34. Muennig P, Khan K. Designing and conducting cost-effectiveness analyses in medicine and health care. San Francisco: Jossey-Bass, 2002.

    Google Scholar 

  35. Centers for Medicare and Medicaid Services. Medicare hospital outpatient prospective payment system. http://www.cms.hhs.gov/HospitalOutpatientPPS/HORD/itemdetail.asp?filterType=none&filterByDID=9&sortByDID=3&sortOrder=descending&itemID=CMS1185569. Accessed 23 August 2009.

  36. National Cancer Databank. Patterns of diagnosis and treatment for selected cancers, 2006. http://cromwell.facs.org/BMarks/BMPub/Ver10/DxRx/BMPub_DxRx.cfm. Accessed 23 August 2009.

  37. Sarasin FP, Bounameaux H. Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery. Arch Surg. 1996;131:694–8.

    CAS  PubMed  Google Scholar 

  38. Hovens MMC, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost. 2006;4:1470–5.

    Article  CAS  PubMed  Google Scholar 

  39. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:338S–400S.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ciarán T. Bradley MD, MA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bradley, C.T., Brasel, K.J., Miller, J.J. et al. Cost-Effectiveness of Prolonged Thromboprophylaxis After Cancer Surgery. Ann Surg Oncol 17, 31–39 (2010). https://doi.org/10.1245/s10434-009-0671-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0671-6

Keywords

Navigation